Central nervous system diseases, including brain traumatism
Coagulation and haematology
Autoimmune diseases and inflammation
Diabetes and other metabolic diseases
The biomarker-driven drug development across the industry is driving the group's personalised healthcare strategy across many therapeutic areas for different intended uses.
Roche Diagnostics evaluates new biomarker opportunities by continuously monitoring universities, start-ups, medical and research institutes, mid sized and large companies.
The goal is to identify biomarkers that address significant unmet medical needs to enable novel and important physician decision making along the entire continuum of a patient’s journey.
Roche’s tests provide crucial knowledge about the different diseases during the whole spectrum of care (screening - diagnosis - prognosis - prediction - monitoring), enabling physicians and caretakers to intervene early and to actively manage patients’ health conditions.
If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.